T
Thomas D. Penning
Researcher at AbbVie
Publications - 94
Citations - 3185
Thomas D. Penning is an academic researcher from AbbVie. The author has contributed to research in topics: Poly ADP ribose polymerase & PARP inhibitor. The author has an hindex of 25, co-authored 94 publications receiving 3034 citations. Previous affiliations of Thomas D. Penning include G. D. Searle & Company & Pharmacia.
Papers
More filters
Journal ArticleDOI
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Cherrie K. Donawho,Yan Luo,Yanping Luo,Thomas D. Penning,Joy Bauch,Jennifer J. Bouska,Velitchka Bontcheva-Diaz,Bryan F. Cox,Theodore L. DeWeese,Larry E. Dillehay,Debra Ferguson,Nayereh S. Ghoreishi-Haack,David R. Grimm,Ran Guan,Edward K. Han,Rhonda R. Holley-Shanks,Boris Hristov,Kenneth B. Idler,Ken Jarvis,Eric F. Johnson,Lawrence Kleinberg,Vered Klinghofer,Loren M. Lasko,Xuesong Liu,Kennan C. Marsh,Thomas McGonigal,Jonathan A. Meulbroek,Amanda M. Olson,Joann P. Palma,Luis E. Rodriguez,Yan Shi,Jason Stavropoulos,Alan C. Tsurutani,Gui Dong Zhu,Saul H. Rosenberg,Vincent L. Giranda,David Frost +36 more
TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.
Patent
Substituted pyrazolyl benzenesulfonamides
Talley John J,Thomas D. Penning,Paul W. Collins,Rogier Donald J,James W. Malecha,Julie M. Miyashiro,Stephen R. Bertenshaw,Ish K. Khanna,Matthew J. Graneto,Roland S. Rogers,Jeffery S. Carter +10 more
TL;DR: In this article, a class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders, and compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically acceptable salt thereof.
Journal ArticleDOI
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Thomas D. Penning,Gui-Dong Zhu,Viraj B. Gandhi,Jianchun Gong,Xuesong Liu,Yan Shi,Vered Klinghofer,Eric F. Johnson,Cherrie K. Donawho,David Frost,Velitchka Bontcheva-Diaz,Jennifer J. Bouska,Donald J. Osterling,Amanda M. Olson,Kennan C. Marsh,Yan Luo,Vincent L. Giranda +16 more
TL;DR: Compound 3a is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in conjunction with either carboplatin or cyclophosphamide.
Journal ArticleDOI
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Xuesong Liu,Yan Shi,David Maag,Joann P. Palma,Melanie J. Schroeder Patterson,Paul Ellis,Bruce W. Surber,Damien B. Ready,Niru B. Soni,Uri S. Ladror,Allison J. Xu,Ramesh Iyer,John E. Harlan,Larry R. Solomon,Cherrie K. Donawho,Thomas D. Penning,Eric F. Johnson,Alexander R. Shoemaker +17 more
TL;DR: It is found that the nitroso metabolite of iniparib forms adducts with many cysteine-containing proteins in tumor cells, and the primary mechanism of action for inipirib is likely not via inhibition of PARP activity.
Journal ArticleDOI
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Joann P. Palma,Yi-Chun Wang,Luis E. Rodriguez,Debra Montgomery,Paul Ellis,Gail Bukofzer,Amanda Niquette,Xuesong Liu,Yan Shi,Loren M. Lasko,Gui-Dong Zhu,Thomas D. Penning,Vincent L. Giranda,Saul H. Rosenberg,David Frost,Cherrie K. Donawho +15 more
TL;DR: Robust ABT-888+TMZ efficacy is observed across a spectrum of tumor types, including orthotopic and metastatic implantation, and this novel combination may broaden the clinical use of TMZ beyond melanoma and glioma.